
Petrus Järvinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4192025/publications.pdf Version: 2024-02-01



DETDUS LÃOVINEN

#	Article	IF	CITATIONS
1	Genomic profile of pseudomyxoma peritonei analyzed using nextâ€generation sequencing and immunohistochemistry. International Journal of Cancer, 2015, 136, E282-9.	5.1	66
2	Decision Aids for Prostate Cancer Screening Choice. JAMA Internal Medicine, 2019, 179, 1072.	5.1	40
3	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium. European Urology Oncology, 2021, 4, 473-482.	5.4	33
4	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patientâ€derived cancer cells. International Journal of Cancer, 2019, 144, 1356-1366.	5.1	29
5	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
6	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Modern Pathology, 2021, 34, 2229-2241.	5.5	25
7	Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin. International Journal of Colorectal Disease, 2014, 29, 999-1007.	2.2	23
8	Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. Human Pathology, 2016, 54, 47-54.	2.0	23
9	Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS ONE, 2017, 12, e0189272.	2.5	23
10	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncolmmunology, 2020, 9, 1761229.	4.6	22
11	Patient Experience of Systematic Versus Fusion Prostate Biopsies. European Urology Oncology, 2018, 1, 202-207.	5.4	20
12	Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. Scandinavian Journal of Urology, 2018, 52, 419-426.	1.0	16
13	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. Oncolmmunology, 2022, 11, 1993042.	4.6	16
14	Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei. PLoS ONE, 2017, 12, e0174898.	2.5	15
15	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. Scandinavian Journal of Urology, 2016, 50, 380-386.	1.0	12
16	Carbonic anhydrase <scp>II</scp> : a novel biomarker for pseudomyxoma peritonei. Apmis, 2017, 125, 207-212.	2.0	11
17	Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the) Tj ETQq1 1 0.784	314 rgBT / 1.0	Overlock 10
	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the		

prediction of adverse findings and biochemical recurrence after radical prostatectomy. PLoS ONE, 2020, 15, e0235779.

2.5 8

Petrus JÃ**r**vinen

#	Article	IF	CITATIONS
19	Cardiac Stress Reactivity and Recovery of Novelty Seekers. International Journal of Behavioral Medicine, 2009, 16, 236-240.	1.7	6
20	Randomized Trials Show a Consistent Benefit of Radical Prostatectomy on Mortality Outcomes. Journal of Urology, 2019, 202, 1106-1108.	0.4	6
21	Should patients with lowâ€risk renal cell carcinoma be followed differently after nephronâ€sparing surgery vs radical nephrectomy?. BJU International, 2021, 128, 386-394.	2.5	5
22	Active surveillance versus initial surgery in the long-term management of Bosniak IIF–IV cystic renal masses. Scientific Reports, 2022, 12, .	3.3	5
23	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non–organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. European Urology Focus, 2020, 7, 1316-1323.	3.1	4
24	Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. Scandinavian Journal of Urology, 2020, 54, 413-419.	1.0	3
25	Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA -2 study). Research and Reports in Urology, 2018, Volume 10, 181-187.	1.0	2
26	Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. Urologia Internationalis, 2019, 102, 390-398.	1.3	1
27	Hand-assisted laparoscopic versus open partial nephrectomy in patients with T1 renal tumor: Comparative perioperative, functional and oncological outcome. Scandinavian Journal of Urology, 2015, 49, 446-452.	1.0	1
28	Title is missing!. , 2020, 15, e0235779.		0
29	Title is missing!. , 2020, 15, e0235779.		0
30	Title is missing!. , 2020, 15, e0235779.		0
31	Title is missing!. , 2020, 15, e0235779.		0